科学之前的政策：医用大麻法律与科学证据
Policy Ahead of the Science: Medical Cannabis Laws Versus Scientific Evidence.
作者信息
Burnett Gregory Malik, Gorelick David A, Hill Kevin P
机构信息
Center of Addiction Medicine, University of Maryland Midtown Campus, 827 Linden Avenue 4th Floor, Suite 405, Baltimore MD 21201, USA; Division of Addiction Research and Treatment, Department of Psychiatry, University of Maryland School of Medicine, 22 S. Greene Street S-1-D-04, Baltimore, MD 21201, USA.
Department of Psychiatry, University of Maryland School of Medicine, PO Box, 21247, MPRC-Tawes Building, Baltimore, MD 21228, USA.
出版信息
Psychiatr Clin North Am. 2022 Sep;45(3):347-373. doi: 10.1016/j.psc.2022.05.002. Epub 2022 Aug 1.
Forty-one US jurisdictions (37 states) have legalized comprehensive medical cannabis programs since 1996. The number of qualifying conditions per jurisdiction varies from 5 to 29. Five (12%) of 42 qualifying conditions have conclusive or substantial evidence of efficacy and are listed in more than half of all jurisdictions. Half (50%) of qualifying conditions have no or insufficient scientific evidence of benefit from medical cannabis; 9% of qualifying conditions have limited evidence of harm from medical cannabis. The mean number of qualifying conditions per jurisdiction and the proportion of conditions with and without evidence of benefit have not changed since 1996.
自1996年以来，美国41个司法管辖区（37个州）已将全面的医用大麻计划合法化。每个司法管辖区的合格病症数量从5种到29种不等。42种合格病症中有5种（12%）有确凿或大量疗效证据，且在所有司法管辖区中半数以上都有列出。半数（50%）合格病症没有或仅有不足的科学证据表明医用大麻有益；9%的合格病症有医用大麻危害的有限证据。自1996年以来，每个司法管辖区的合格病症平均数量以及有和没有益处证据的病症比例均未改变。
Zotero 插件